TP53 mutations are associated with poorer prognosis in ER-positive metastatic breast cancer, whereas in ER-negative cases, TP53 mutations may have a protective effect (Kim et al., 2017; Rajendran and Deng, 2017). The gene discussed is TP53; the disease is breast carcinoma.